Loading...
XTAE
PPBT
Market cap11kUSD
Dec 04, Last price  
1.30ILS
1D
8.33%
1Q
-13.33%
Jan 2017
-99.89%
Name

Purple Biotech Ltd

Chart & Performance

D1W1MN
XTAE:PPBT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
205.71%
Rev. gr., 5y
115.44%
Revenues
0k
00000901,0001,000,0001,000,0001,000,000-320,000-910,00000
Net income
-7m
L-63.58%
-703-2,628,000-5,252,000-4,202,000-12,125,000-12,272,000-5,200,000-6,109,000-12,405,000-18,463,000-20,825,000-19,880,000-7,240,000
CFO
-14m
L-25.27%
-253-512,000-4,526,000-3,308,000-6,262,000-8,627,000-8,480,000-5,581,000-12,092,000-15,071,000-16,735,000-19,226,000-14,367,000
Dividend
Oct 30, 201295.9805 ILS/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
URL
https://purple-biotech.com/
IPO date
Sep 03, 1978
Employees
20
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT